Molecular assays for monitoring HIV infection and antiretroviral therapy

References

• Chen Z, Luckay A, Sodora DL et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J. Virol.71, 3953–3960 (1997).
   PubMed Web of Science ®Google Scholar
• Gao F, Yue L, Robertson DL et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol.68, 7433–447 (1994).
   PubMed Web of Science ®Google Scholar
• Gao F, Yue L, White AT et al. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature358, 495–499 (1992).
   PubMedGoogle Scholar
• Butler IF, Pandrea I, Marx PA, Apetrei C. HIV genetic diversity: biological and public health consequences. Curr. HIV Res.5, 23–45 (2007).
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med.126, 946–954 (1997).
   PubMed Web of Science ®Google Scholar
• Raboud J, Montaner M, Conway JSG et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS12, 1619–1624 (1998).
   PubMed Web of Science ®Google Scholar
• Berger A, Preiser W. Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. JAC Antiviral49, 713–721 (2002).
   Google Scholar
• Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet353(9171), 2195–2199 (1999).
   PubMed Web of Science ®Google Scholar
• Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS14(9), F83–F93 (2000).
   PubMed Web of Science ®Google Scholar
• Cingolani A, Antinori A, Rizzo MG et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS16(3), 369–379 (2002).
   PubMed Web of Science ®Google Scholar
• Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS16(5), 727–736 (2002).
   PubMed Web of Science ®Google Scholar
• Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS16(2), 209–218 (2002).
   PubMed Web of Science ®Google Scholar
• Haupts S, Ledergerber B, Boni J et al. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir. Ther.8(5), 443–454 (2003).
   PubMed Web of Science ®Google Scholar
• Salzberger B, Marcus U, Vielhaber B et al. German–Austrian recommendations for the antiretroviral therapy of HIV-infection. Eur. J. Med. Res.9(11), 491–504 (2004).
   PubMedGoogle Scholar
• Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med.7(8), 487–503 (2006).
   PubMed Web of Science ®Google Scholar
• Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA296(7), 827–843 (2006).
   PubMed Web of Science ®Google Scholar
• Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA). Mol. Biotechnol.20, 163–179 (2002).
   PubMed Web of Science ®Google Scholar
• Loens K, Ursi D, Ieven M et al. Detection of Mycoplasma pneumoniae in spiked clinical samples by nucleic acid sequence-based amplification. J. Clin. Microbiol.40, 1339–1345 (2002).
   PubMedGoogle Scholar
• van Gemen B, Van Beuningen R, Nabbe A, van Strijp DS, Lens P, Kievits T. A one tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J. Virol. Methods49, 157–168 (1994).
   PubMed Web of Science ®Google Scholar
• Weusten JJ, Carpay WM, Oosterlaken TA, von Zuijlen MC, van de Wiel PA. Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res.30(6), e26 (2002).
   Google Scholar
• Murphy DG, Coté L, Fauvel M, René P, Vincelette J. Multicenter comparison of Roche Cobas Amplicor Monitor version 1.5, Organon Teknika NucliSens QT with extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol.38, 4034–4041 (2000).
   PubMedGoogle Scholar
• Berger A, Scherzed L, Stürmer M, Preiser W, Doerr HW, Rabenau HF. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor™Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor™ and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J. Clin. Virol.33, 43–51 (2005).
   PubMedGoogle Scholar
• Pasloske BL, Walkerpeach CR, Obermoeller RD, Winkler M, DuBois DB. Armored RNA technology for production of ribonucleaseresistent viral RNA controls and standards. J. Clin. Microbiol.36, 3590–3594 (1998).
   PubMed Web of Science ®Google Scholar
• Swanson P, Harris BJ, Holzmayer V, Devare SG, Schochetman G, Hackett J Jr. Quantification of HIV-1 group M (subtypes A–G) and group O by the LCx HIV RNA quantitative assay. J. Virol. Methods89, 97–108 (2000).
   PubMedGoogle Scholar
• Swanson P, Soriano V, Devare SG, Hackett J Jr. Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0. J. Clin. Microbiol.39, 862–870 (2001).
   PubMedGoogle Scholar
• Swanson P, de Mendoza C, Joshi Y et al. Impact of human immunodeficiency virus type 1 (HIV-1) Genetic diversity on performance of four commercial viral load assays: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0 and NucliSens HIV-1 QT. J. Clin. Microbiol.43, 3860–3868 (2005).
   PubMed Web of Science ®Google Scholar
• Troonen H, Grey H, Michel G. Multicenter study of the LCx HIV RNA quantitative assay a new competitive reverse transcriptase-PCR which targets pol genomic region of HIV-1 for the measurement of type B, non-type B and group O HIV-1 RNA. Clin. Chem. Lab. Med.40, 698–704 (2002).
   PubMedGoogle Scholar
• de Mendoza C, Lu W, Machucha A, Sainz M, Castilla J, Soriano V. Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. J. Med. Virol.64, 217–222 (2001).
   PubMedGoogle Scholar
• de Mendoza C, Alcam J, Sainz M, Folgueira D, Soriano V. Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma. J. Clin. Microbiol.40, 1518–1521 (2002).
   PubMedGoogle Scholar
• Gueudin M, Plantier JC, Lemée V et al. Evaluation of the Roche Cobas TaqMan and Abbott realtime extraction-quantification systems for HIV-1 subtypes. AIDS44(5), 500–505 (2007).
   Google Scholar
• Foulongne V, Montes B, Didelot-Rousseau M-N, Segondy M. Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma. J. Clin. Microbiol.44(8), 2963–2966 (2006).
   PubMed Web of Science ®Google Scholar
• Lam HY, Chen JH, Wong KH et al. Evaluation of NucliSens EasyQ HIV-1 assay for quantification of HIV-1 subtypes prevalent in South-East Asia. J. Clin. Virol.38(1), 39–43 (2007).
   PubMed Web of Science ®Google Scholar
• Gottesman BS, Grossman Z, Lorber M et al. Comparative performance of the Amplicor HIV-1 Monitor Assay versus NucliSens EasyQ in HIV subtype C-infected patients. J. Med. Virol.78(7), 883–887 (2006).
   PubMed Web of Science ®Google Scholar
• Berger A, Scherzed L, Stürmer M, Preiser W, Doerr HW, Rabenau HF. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor™Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor™ and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J. Clin. Virol.33, 43–51 (2005).
   PubMedGoogle Scholar
• Swanson P, Holzmayer V, Huang S et al. Performance of automated Abbott RealTime™ HIV-1 assay on a genetically diverse panel of specimens from London: comparison to Versant HIV-1 RNA 3.0, Amplicor HIV-1 Monitor v1.5, and LCx® HIV RNA Quantitative assays. J. Virol. Methods137, 184–192 (2006).
   PubMed Web of Science ®Google Scholar
• Swanson P, Huang S, Abravaya K et al. Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to Versant HIV-1 RNA 3.0 and Amplicor HIV-1 Monitor v1.5 usin serial dilutions of 39 group M an O viruses. J. Virol. Methods.141, 49–57 (2007).
   PubMed Web of Science ®Google Scholar
• Gomes P, Palma AC, Cabanas J et al. Comparison of the COBAS TAQMAN HIV-1 HPS with VERSANT HIV-1 RNA 3.0 assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes. J. Virol. Methods.135(2), 223–228 (2006).
   PubMed Web of Science ®Google Scholar
• Sturmer M, Berger A, Preiser W. HIV-1 genotyping: comparison of two commercially available assays. Expert Rev. Mol. Diagn.4(3), 281–291 (2004).
   PubMed Web of Science ®Google Scholar
• Sturmer M, Doerr HW, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir. Ther.8(3), 239–244 (2003).
   PubMed Web of Science ®Google Scholar
• Sturmer M, Doerr HW, Preiser W. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion? Curr. Drug Targets Infect. Disord.3(4), 373–382 (2003).
   PubMedGoogle Scholar
• Elbeik T, Hoo BS, Campodonico ME et al.In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/ml that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J. Hum. Virol.4(6), 317–328 (2001).
   PubMedGoogle Scholar
• Sturmer M, Berger A, Doerr HW. Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J. Med. Virol.71(4), 475–479 (2003).
   PubMedGoogle Scholar
• Mackie N, Dustan S, McClure MO, Weber JN, Clarke JR. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J. Virol. Methods119(2), 73–78 (2004).
   PubMed Web of Science ®Google Scholar
• Gale HB, Kan VL, Shinol RC. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin. Vaccine Immunol.13(2), 235–238 (2006).
   PubMedGoogle Scholar
• McClernon DR, Ramsey E, Clair MS. Magnetic silica extraction for low-viremia human immunodeficiency virus type 1 genotyping. J. Clin. Microbiol.45(2), 572–574 (2007).
   PubMedGoogle Scholar
• Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. Br. Med. J.331(7529), 1368 (2005).
   PubMed Web of Science ®Google Scholar
• Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis.192(6), 958–966 (2005).
   PubMed Web of Science ®Google Scholar
• Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J. Acquir. Immune Defic. Syndr.41(5), 573–581 (2006).
   PubMed Web of Science ®Google Scholar
• Shet A, Berry L, Mohri H et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr.41(4), 439–446 (2006).
   PubMed Web of Science ®Google Scholar
• Bezemer D, de Ronde A, Prins M et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antiviral Ther.11(2), 173–178 (2006).
   PubMed Web of Science ®Google Scholar
• Flys T, Nissley DV, Claasen CW et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis.192(1), 24–29 (2005).
   PubMedGoogle Scholar
• Metzner KJ, Rauch P, Walter H et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS19(16), 1819–1825 (2005).
   PubMed Web of Science ®Google Scholar
• Church JD, Jones D, Flys T et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J. Mol. Diagn.8(4), 430–432 (2006).
   PubMed Web of Science ®Google Scholar
• Shi C, Eshleman SH, Jones D et al. LigAmp for sensitive detection of single-nucleotide differences. Nat. Methods1(2), 141–147 (2004).
   PubMed Web of Science ®Google Scholar